Xenon Pharmaceuticals Inc (XENE)

17.27 -0.34  -1.93% NASDAQ Jul 30, 20:00 USD

Xenon Pharmaceuticals Revenue (TTM):

29.45M for March 31, 2021
View 4,000+ financial data types
View Full Chart

Revenue (TTM) Chart

Export Data
Save Image
Print Image

Historical Revenue (TTM) Data

View and export this data going back to 2014. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2021 29.45M
Dec. 31, 2020 32.17M
Sept. 30, 2020 30.34M
June 30, 2020 27.29M
March 31, 2020
Dec. 31, 2019
Sept. 30, 2019
June 30, 2019
March 31, 2019
Dec. 31, 2018
Sept. 30, 2018
June 30, 2018
March 31, 2018
Dec. 31, 2017 0.311M
Sept. 30, 2017 0.671M
June 30, 2017 0.82M
March 31, 2017 1.218M
Dec. 31, 2016 1.803M
Sept. 30, 2016 4.654M
June 30, 2016 8.535M
March 31, 2016 12.17M
Dec. 31, 2015 15.58M
Sept. 30, 2015 17.23M
June 30, 2015 26.13M
March 31, 2015 27.38M
Dec. 31, 2014 28.37M
Sept. 30, 2014 29.08M
June 30, 2014 26.67M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.


Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Range, Past 5 Years

Minimum 0.311M Dec 2017
Maximum 32.17M Dec 2020
Average 12.87M


Xenon Pharma secures $100M via equity raise
SA Breaking News 03/10 01:40 ET



Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.